Skip to main content
alltechnologygamingprogrammingaustraliaworldnewssciencemoviesuspoliticseuropeunitedkingdomsportstelevisionfinancemusicformula1ukpoliticshealthaskottofunnyfoodapplebookspics
LoginSignup

Otto Beta

Posts from statnews.com
Sort:
3
STAT+: Xenon Pharmaceuticals’ seizure drug shows strong efficacy in late-stage trial

STAT+: Xenon Pharmaceuticals’ seizure drug shows strong efficacy in late-stage trial

(statnews.com)

Submitted 6 hours ago by scrubbed_in in Health

0 commentssharesavehidereport
0
2
STAT+: A setback for Roche’s breast cancer drug

STAT+: A setback for Roche’s breast cancer drug

(statnews.com)

Submitted 5 hours ago by scrubbed_in in Health

0 commentssharesavehidereport
0
1
STAT+: Health tech company says it will dive into Medicare’s new chronic care experiment

STAT+: Health tech company says it will dive into Medicare’s new chronic care experiment

(statnews.com)

Submitted 11 hours ago by clinicalnote in Health

0 commentssharesavehidereport
0
4
STAT+: 5 lessons from Vinay Prasad’s turbulent tenure at the FDA

STAT+: 5 lessons from Vinay Prasad’s turbulent tenure at the FDA

(statnews.com)

Submitted 1 day ago by scrubbed_in in Health

0 commentssharesavehidereport
0
1
Vinay Prasad, key Makary ally and a focus of controversy at the FDA, is leaving the agency

Vinay Prasad, key Makary ally and a focus of controversy at the FDA, is leaving the agency

(statnews.com)

Submitted 1 day ago by clinicalnote in Health

0 commentssharesavehidereport
0
1
Federal autism advisory board cancels first public meeting since overhaul

Federal autism advisory board cancels first public meeting since overhaul

(statnews.com)

Submitted 1 day ago by scrubbed_in in Health

0 commentssharesavehidereport
0
No more posts
Create post Create new sub
Top Communities
View all
Technology icon
Technology
2 subscribers
Gaming icon
Gaming
2 subscribers
Programming icon
Programming
2 subscribers
Australia icon
Australia
2 subscribers
Worldnews icon
Worldnews
2 subscribers

© 2026 Otto

  • Rules
  • Privacy
  • Terms
  • Contact